Neoplasms

All Conditions

Digestive System Diseases

Rare Diseases

Adenocarcinoma

Stomach Neoplasms

Carcinoma

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Stomach Cancer

All Drugs and Chemicals

Antineoplastic Agents

Micronutrients

Vitamins

Antibodies

Capecitabine

Leucovorin

Fluorouracil

Levoleucovorin

Oxaliplatin

Antibodies, Bispecific

Immunoglobulins

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Folinic Acid

Volrustomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)

Rilvegostomig plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)

AZD0901 plus volrustomig and 5-fluorouracil or capecitabine

AZD0901 plus rilvegostomig and 5-fluorouracil or capecitabine

AZD7789 plus XELOX (oxaliplatin and capecitabine) or FOLFOX (oxaliplatin and 5-FU/CF)

AZD0901 plus AZD7789 and 5-fluorouracil or capecitabine

an anti PD-1 and anti-TIGIT bispecific antibody; IV infusion

Rilvegostomig

an anti PD-1 and anti CTLA-4 bispecific antibody; IV infusion

Volrustomig

5-fluorouracil 400 mg/m\^2 IV, oxaliplatin 85 mg/m\^2, leucovorin 400 mg/m\^2 (or levoleucovorin 200 mg/m\^2 when locally preferred and available), day 1, 5-fluorouracil 1200 mg/m\^2 IV 24 h day 1-2

FOLFOX

capecitabine 1000 mg/m\^2 BID, days 1 to 14, oxaliplatin 130 mg/m\^2, day 1

XELOX

an anti PD 1 and anti TIM 3 bispecific antibody; IV infusion

AZD7789

AZD0901

5-Fluorouracil

AstraZeneca Clinical Study Information Center

This is a Phase II, open-label, multi-drug, multi-centre study designed to assess the efficacy, safety, tolerability, pharmacokinetics, and immunogenicity of novel combination therapies in participants with locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma.

Approximately 240 participants will be assigned across 6 substudies, with approximately 40 evaluable participants of the confirmed recommend dose by SRC for study intervention in each corresponding substudy.

Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment:

https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

the proportion of participants who have a confirmed complete response or confirmed partial response, as determined by the Investigator at local site per RECIST 1.1.

the proportion of participants alive and progression-free at 6 months.

the time from the start of study intervention until progression per RECIST 1.1 as assessed by the Investigator at the local site or death due to any cause in the absence of progression.

the time from the start of study intervention until the date of death due to any cause.

the time from the date of first documented confirmed response until date of documented progression per RECIST 1.1 by the Investigator at local site or death due to any cause in the absence of disease progression.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	NCT05702229	Gastric Cancer	Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine	18 Years -	AstraZeneca
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	NCT05702229	Gastric Cancer	Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine	18 Years -	AstraZeneca
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	NCT05702229	Gastric Cancer	Rilvegostomig Volrustomig FOLFOX XELOX AZD7789 AZD0901 5-Fluorouracil Capecitabine	18 Years -	AstraZeneca

Spots Global Cancer Trial Database for metatstatic

Every month we try and update this database with for metatstatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for metatstatic

Every month we try and update this database with for metatstatic cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for metatstatic cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.